Table 3.
Overall response rates (ORR) and disease control rates (DCR) (n = 70 patients totally)
| Patients with measurable disease (and at least one tumor assessment) | Cutaneous melanoma | Mucosal melanoma | Melanoma of unknown primary | |||
|---|---|---|---|---|---|---|
| N | % | N | % | N | % | |
| No. patients (%) | 55 | 100 | 6 | 100 | 9 | 100 |
| Response pattern (acc. to RECIST) | ||||||
| Complete response | – | – | – | |||
| Partial response | 9 | 16 | 1 | 17 | 1 | 11 |
| Stable disease | 7 | 13 | 2 | 33 | 1 | 11 |
| Progressive disease | 39 | 71 | 3 | 50 | 7 | 78 |
| Best ORR (according to RECIST) | ||||||
| ORR (=CR + PR) | 9 | 16 | 1 | 17 | 1 | 11 |
| ORR at week 12 | 7 | 13 | 1 | 17 | – | |
| ORR at week 24 | 6 | 11 | 1 | 17 | – | |
| Best DCR (according to RECIST) | ||||||
| DCR (=CR + PR + SD) | 16 | 29 | 3 | 50 | 2 | 22 |
| DCR at week 12 | 15 | 27 | 3 | 50 | 2 | 22 |
| DCR at week 24 | 10 | 18 | 1 | 17 | 1 | 11 |
CR complete response, PR partial response, RECIST response evaluation criteria in solid tumors, SD stable disease